In a regulatory filing, BioMarin worldwide R&D president Henry Fuchs disclosed the sale of 35,341 common shares of the company on March 5 at a price of $85.1814 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMRN:
- New Share Price & Shareholder Rights Risk for Biomarin Pharmaceutical Inc. – What’s the Latest?
- BioMarin discloses receipt of subpoena from U.S. Department of Justice
- BioMarin price target lowered to $107 from $115 at Piper Sandler
- BioMarin price target lowered to $130 from $150 at BofA
- BioMarin sees 2024 non-GAAP EPS $2.60-$2.80, consensus $1.96
